Scalper1 News
When it comes to buyouts among drugmakers, it’s hard to keep up with Valeant Pharmaceuticals’ (VRX) rapid pace of acquisitions. The Canadian drugmaker, which has already made a flurry of acquisitions this year, leads the 42-stock ethical drug makers group with a 99 Composite Rating. Other highly rated players in the group include Horizon (HZNP), Eli Lilly (LLY), Jazz Pharmaceuticals (JAZZ), Novo Nordisk (NVO) and AbbVie (ABBV). The group ranked Scalper1 News
Scalper1 News